{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T16:27:25Z","timestamp":1770827245802,"version":"3.50.1"},"reference-count":40,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:00:00Z","timestamp":1747699200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Famille Cassar Fund of Universit\u00e9 de Montr\u00e9al"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Background: Allogeneic hematopoietic cell transplant (alloHCT) is a curative option for relapsed\/refractory B-cell lymphomas (BCLs), but its role in the evolving field of cellular therapy is increasingly unclear as recent advances in transplant procedures have improved outcomes. Methods: This retrospective, single-center study included 55 BCL patients (large B-cell lymphoma\u2014LBCL; indolent BCL; and mantle cell lymphoma\u2014MCL) treated with alloHCT from 2015 to 2023 at H\u00f4pital Maisonneuve-Rosemont. Primary endpoints were overall survival (OS) and progression-free survival (PFS); secondary endpoints included NRM and GVHD incidence. Results: A total of 55 patients were included (25 LBCLs, 16 indolent BCLs, 14 MCLs), and 76% of LBCLs were of indolent origin (Richter transformation, transformed follicular lymphoma). After a median follow-up of 6.1, 5.8 and 2.4 years for LBCLs, indolent BCLs and MCLs, their 5-year PFS and OS were 57.2% (IC 95%: 34.2\u201374.7) and 62.8% (IC 95%: 37.9\u201380.0), 81.2% (IC 95%: 52.5\u201393.5) and 93.8% (IC 95%: 63.2\u201399.1), and 39.0% (IC 95%: 14.3\u201363.3) and 68.1% (IC 95%: 35.4\u201386.8), respectively. The 5-year NRM was 16.9% (IC 95%: 8.2\u201328.3) with a relapse incidence of 23.4%. Overall\/grade 3\u20134 acute GVHD occurred in 43.6% and 18.1% of patients. At 3 years, overall\/moderate or severe chronic GVHD incidence was 49% and 34.5%. Conclusions: AlloHCT remains a potentially curative option and should be considered for fit patients with chemosensitive FL or LBCLs of indolent origin and a low comorbidity index.<\/jats:p>","DOI":"10.3390\/curroncol32050285","type":"journal-article","created":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T04:48:18Z","timestamp":1747716498000},"page":"285","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Allogeneic Hematopoietic Cell Transplant for B-Cell Lymphomas in the Era of Novel Cellular Therapies: Experience from a Tertiary Canadian Center"],"prefix":"10.3390","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9281-8015","authenticated-orcid":false,"given":"Mathias","family":"Castonguay","sequence":"first","affiliation":[{"name":"Hematology-Oncology and Cell Therapy University Institute, H\u00f4pital Maisonneuve-Rosemont Research Center, Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC H1T 2M4, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7716-6864","authenticated-orcid":false,"given":"Jean","family":"Roy","sequence":"additional","affiliation":[{"name":"Hematology-Oncology and Cell Therapy University Institute, H\u00f4pital Maisonneuve-Rosemont Research Center, Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC H1T 2M4, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2638-5773","authenticated-orcid":false,"given":"Jean-S\u00e9bastien","family":"Claveau","sequence":"additional","affiliation":[{"name":"Hematology-Oncology and Cell Therapy University Institute, H\u00f4pital Maisonneuve-Rosemont Research Center, Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC H1T 2M4, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7882-9335","authenticated-orcid":false,"given":"Sylvie","family":"Lachance","sequence":"additional","affiliation":[{"name":"Hematology-Oncology and Cell Therapy University Institute, H\u00f4pital Maisonneuve-Rosemont Research Center, Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC H1T 2M4, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1460-7287","authenticated-orcid":false,"given":"Jean-S\u00e9bastien","family":"Delisle","sequence":"additional","affiliation":[{"name":"Hematology-Oncology and Cell Therapy University Institute, H\u00f4pital Maisonneuve-Rosemont Research Center, Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC H1T 2M4, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Kiss","sequence":"additional","affiliation":[{"name":"Hematology-Oncology and Cell Therapy University Institute, H\u00f4pital Maisonneuve-Rosemont Research Center, Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC H1T 2M4, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Cohen","sequence":"additional","affiliation":[{"name":"Hematology-Oncology and Cell Therapy University Institute, H\u00f4pital Maisonneuve-Rosemont Research Center, Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC H1T 2M4, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Fleury","sequence":"additional","affiliation":[{"name":"Hematology-Oncology and Cell Therapy University Institute, H\u00f4pital Maisonneuve-Rosemont Research Center, Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC H1T 2M4, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigina","family":"Mollica","sequence":"additional","affiliation":[{"name":"Hematology-Oncology and Cell Therapy University Institute, H\u00f4pital Maisonneuve-Rosemont Research Center, Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC H1T 2M4, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1899-0164","authenticated-orcid":false,"given":"Imran","family":"Ahmad","sequence":"additional","affiliation":[{"name":"Hematology-Oncology and Cell Therapy University Institute, H\u00f4pital Maisonneuve-Rosemont Research Center, Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC H1T 2M4, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadia","family":"Bambace","sequence":"additional","affiliation":[{"name":"Hematology-Oncology and Cell Therapy University Institute, H\u00f4pital Maisonneuve-Rosemont Research Center, Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC H1T 2M4, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L\u00e9a","family":"Bernard","sequence":"additional","affiliation":[{"name":"Hematology-Oncology and Cell Therapy University Institute, H\u00f4pital Maisonneuve-Rosemont Research Center, Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC H1T 2M4, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5921-1692","authenticated-orcid":false,"given":"Denis-Claude","family":"Roy","sequence":"additional","affiliation":[{"name":"Hematology-Oncology and Cell Therapy University Institute, H\u00f4pital Maisonneuve-Rosemont Research Center, Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC H1T 2M4, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guy","family":"Sauvageau","sequence":"additional","affiliation":[{"name":"Hematology-Oncology and Cell Therapy University Institute, H\u00f4pital Maisonneuve-Rosemont Research Center, Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC H1T 2M4, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7029-1769","authenticated-orcid":false,"given":"Olivier","family":"Veilleux","sequence":"additional","affiliation":[{"name":"Hematology-Oncology and Cell Therapy University Institute, H\u00f4pital Maisonneuve-Rosemont Research Center, Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC H1T 2M4, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e423","DOI":"10.3324\/haematol.2015.129452","article-title":"Tandem autologous-allogeneic stem cell transplantation as a feasible and effective procedure in high-risk lymphoma patients","volume":"100","author":"Crocchiolo","year":"2015","journal-title":"Haematologica"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1016\/j.bbmt.2015.05.016","article-title":"Phase II Trial of Tandem High-Dose Chemotherapy with Autologous Stem Cell Transplantation Followed by Reduced-Intensity Allogeneic Stem Cell Transplantation for Patients with High-Risk Lymphoma","volume":"21","author":"Chen","year":"2015","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.bbmt.2011.11.028","article-title":"Tandem autologous-allogeneic nonmyeloablative sibling transplantation in relapsed follicular lymphoma leads to impressive progression-free survival with minimal toxicity","volume":"18","author":"Cohen","year":"2012","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.bbmt.2009.04.004","article-title":"Graft-versus-host disease prophylaxis with tacrolimus and mycophenolate mofetil in HLA-matched nonmyeloablative transplant recipients is associated with very low incidence of GVHD and nonrelapse mortality","volume":"15","author":"Sabry","year":"2009","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","article-title":"International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium","volume":"22","author":"Harris","year":"2016","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1182\/blood-2024-194632","article-title":"Hematopoietic Stem Cell Transplantation for Marginal Zone Lymphoma, a Benchmark Study from the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation","volume":"144","author":"Serroukh","year":"2024","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1002\/cncr.31264","article-title":"Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: A combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR","volume":"124","author":"Sureda","year":"2018","journal-title":"Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/s41467-022-34642-6","article-title":"Molecular characterization of Richter syndrome identifies de novo diffuse large B-cell lymphomas with poor prognosis","volume":"14","author":"Hergalant","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/bjh.14046","article-title":"Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation","volume":"174","author":"Fenske","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1038\/sj.bmt.1700781","article-title":"Management of lymphoma recurrence after allogeneic transplantation: The relevance of graft-versus-lymphoma effect","volume":"19","author":"Giralt","year":"1997","journal-title":"Bone Marrow Transpl."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.bbmt.2004.05.008","article-title":"Graft-versus-lymphoma effects: Clinical review, policy proposals, and immunobiology","volume":"10","author":"Grigg","year":"2004","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.bbmt.2010.04.004","article-title":"NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell Transplantation","volume":"16","author":"Pavletic","year":"2010","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.3324\/haematol.2021.279033","article-title":"Allogeneic hematopoietic cell transplantation outcomes in patients with Richter\u2019s transformation","volume":"106","author":"Kim","year":"2021","journal-title":"Haematologica"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1038\/s41409-024-02256-9","article-title":"Allogeneic hematopoietic stem-cell transplantation for patients with Richter transformation: A retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT","volume":"59","author":"Eikema","year":"2024","journal-title":"Bone Marrow Transpl."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1200\/JCO.2012.44.0693","article-title":"Autologous and Allogeneic Stem-Cell Transplantation for Transformed Follicular Lymphoma: A Report of the Canadian Blood and Marrow Transplant Group","volume":"31","author":"Villa","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1182\/blood.V84.4.1050.1050","article-title":"Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin\u2019s lymphoma","volume":"84","author":"Ratanatharathorn","year":"1994","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/j.bbmt.2010.08.001","article-title":"NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation","volume":"16","author":"Porter","year":"2010","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1002\/cncr.29498","article-title":"Long-term sustained disease control in patients with mantle cell lymphoma with or without active disease after treatment with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning","volume":"121","author":"Vaughn","year":"2015","journal-title":"Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1093\/annonc\/mds054","article-title":"Reduced-intensity conditioning allogeneic stem cell transplantation for relapsed\/refractory mantle cell lymphoma: A multicenter experience","volume":"23","author":"Dhedin","year":"2012","journal-title":"Ann. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"4668","DOI":"10.1182\/blood-2018-99-113186","article-title":"Allogeneic Stem Cell Transplantation Overcomes the Negative Prognostic Impact of TP53 Alterations in Mantle Cell Lymphoma","volume":"132","author":"Lin","year":"2018","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1080\/10428194.2023.2241095","article-title":"Allogeneic stem cell transplantation achieves long-term remissions in mantle cell lymphoma, including in TP53-mutated disease","volume":"64","author":"Lew","year":"2023","journal-title":"Leuk. Lymphoma"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3324\/haematol.2016.148510","article-title":"Anti-thymocyte globulin as graft-versus-host disease prevention in the setting of allogeneic peripheral blood stem cell transplantation: A review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation","volume":"102","author":"Baron","year":"2017","journal-title":"Haematologica"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","article-title":"Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis","volume":"388","author":"Hamadani","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa1917635","article-title":"Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease","volume":"382","author":"Zeiser","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2033122","article-title":"Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease","volume":"385","author":"Zeiser","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1182\/blood.2021012021","article-title":"Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: The ROCKstar Study","volume":"138","author":"Cutler","year":"2021","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1182\/blood-2017-07-793786","article-title":"Ibrutinib for chronic graft-versus-host disease after failure of prior therapy","volume":"130","author":"Miklos","year":"2017","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.3324\/haematol.2019.245688","article-title":"History of hematopoietic cell transplantation: Challenges and progress","volume":"105","author":"Granot","year":"2020","journal-title":"Haematologica"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.3324\/haematol.2020.248187","article-title":"Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: Improved outcomes over two decades","volume":"106","author":"Cooper","year":"2021","journal-title":"Haematologica"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"6283","DOI":"10.1182\/bloodadvances.2020003418","article-title":"How much has allogeneic stem cell transplant\u2013related mortality improved since the 1980s? A retrospective analysis from the EBMT","volume":"4","author":"Penack","year":"2020","journal-title":"Blood Adv."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"229","DOI":"10.7326\/M19-2936","article-title":"Survival, Nonrelapse Mortality, and Relapse-Related Mortality After Allogeneic Hematopoietic Cell Transplantation: Comparing 2003\u20132007 Versus 2013\u20132017 Cohorts","volume":"172","author":"McDonald","year":"2020","journal-title":"Ann. Intern. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/joim.12854","article-title":"Trends in patient outcome over the past two decades following allogeneic stem cell transplantation for acute myeloid leukaemia: An ALWP\/EBMT analysis","volume":"285","author":"Canaani","year":"2019","journal-title":"J. Intern. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e573","DOI":"10.1016\/S2352-3026(19)30158-9","article-title":"Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: A European Society for Blood and Marrow Transplantation registry retrospective analysis","volume":"6","author":"Shouval","year":"2019","journal-title":"Lancet Haematol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1182\/blood-2023-179868","article-title":"Five Year Outcomes of Patients with Large B-Cell Lymphoma Treated with Standard-of-Care Axicabtagene Ciloleucel: Results from the US Lymphoma CAR-T Cell Consortium","volume":"142","author":"Spiegel","year":"2023","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1002\/hem3.87","article-title":"Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in the United Kingdom: A real-world intention-to-treat analysis","volume":"8","author":"Wilson","year":"2024","journal-title":"HemaSphere"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41409-023-01949-x","article-title":"Role of allogeneic hematopoietic cell transplant for relapsed\/refractory aggressive B-cell lymphomas in the CART era","volume":"58","author":"Mussetti","year":"2023","journal-title":"Bone Marrow Transpl."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3324\/haematol.2022.281242","article-title":"Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma","volume":"108","author":"Zurko","year":"2023","journal-title":"Haematologica"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1182\/bloodadvances.2019000593","article-title":"Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy","volume":"3","author":"Shadman","year":"2019","journal-title":"Blood Adv."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/5\/285\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:35:28Z","timestamp":1760031328000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/5\/285"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,20]]},"references-count":40,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["curroncol32050285"],"URL":"https:\/\/doi.org\/10.3390\/curroncol32050285","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,20]]}}}